Here are the S-1 registration statements from Aktis Oncology, Inc. (AKTS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow AKTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTS filings page.
Aktis Oncology, Inc. is offering 17,650,000 shares of common stock in an initial public offering, with an expected price range of $16.00 to $18.00 per share and a 30‑day underwriters’ option for up to 2,647,500 additional shares. The company expects about $274.5 million in net proceeds at a $17.00 midpoint, and 52,522,279 shares of common stock outstanding after the deal. Aktis is a clinical-stage radiopharmaceutical company developing miniprotein-based drugs targeting solid tumors, led by Nectin‑4 candidate [225Ac]Ac‑AKY‑1189 in a Phase 1b trial and B7‑H3 program [225Ac]Ac‑AKY‑2519 nearing an IND filing. Eli Lilly has indicated interest in purchasing approximately $100.0 million of stock in the IPO and previously paid $60.0 million upfront plus an equity investment in a discovery collaboration with milestones up to $1.2 billion. Aktis reported net losses of $44.0 million in 2024 and $48.6 million for the nine months ended September 30, 2025, with an accumulated deficit of $141.4 million and $246.2 million in cash, cash equivalents and marketable securities, which it believes will fund operations into 2029.